Latest news articles

Added 3 days ago Drug news

New data presented at EHA meeting for Jakavi for treatment of myelofibrosis. -Novartis.

Novartis announced new findings at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Jakavi data presented...

Added 3 months ago Drug news

Phase III PERSIST-2 trial of SB 1518 in myelofibrosis published in JAMA Oncology.- CTI BioPharma Corp.

CTI BioPharma Corp announced that results from the Phase III PERSIST-2 clinical trial of SB 1518 (pacritinib) have been published...

Added 8 months ago Drug news

Impact Biomedicines to develop fedratinib to treat myelofibrosis and polycythemia vera.

Impact Biomedicines announced its launch to pioneer the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The...

Search all news articles for Other haematologic conditions

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

ALP Lab Assessment

ALP Lab Assessment

Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more


Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Philadelphia chromosome negative chronic myeloproliferative neoplasms include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. The new ESMO Clinical Practice Guidelines...

Added 2 years ago

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR)...

Added 3 years ago

Guideline for the diagnosis and management of myelofibrosis

The purpose of this guideline is to provide a practical, rather than a research, approach to the diagnosis, investigation and management of patients with primary myelofibrosis, as well as post-polycythaemic myelofibrosis (post-PV MF) and...

Added 5 years ago

Search all guidelines for Other haematologic conditions

Journal articles

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.

Ascertainment of cases and disease classification is an acknowledged problem for epidemiological research into haematological malignancies.

Added 9 months ago

Erythrocytosis following testosterone therapy.

A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition.

Added 11 months ago

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors and Haematopoietic and Lymphoid Tissue.

Added 1 year ago

Search all journal articles for Other haematologic conditions